Cooley M&A

OCTOBER 19, 2022

The rise of founder-led, venture capital-backed companies in recent years has coincided with a surge of companies implementing dual-class share structures in connection with their initial public offerings. Biotech Company ViaCyte to Be Acquired by Vertex Pharmaceuticals. Notable public deals.

M&A 69

M&A Initial Public Offering Pharmaceutical Medical 69

Cooley M&A

JANUARY 25, 2023

But it wasn’t all carve outs and concerned investors – even with the headwinds in the industry and beyond, there were still several traditional public M&A deals involving biotechnology or medical device companies, as large pharmaceutical companies continued to have cash to deploy for acquisitions. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Moving into Q2 of 2023, roughly 29% of US public biotech companies traded below their cash value. Why did life sciences outperform the market?

M&A 52

M&A Mergers and Acquisitions Pharmaceutical Acquisitions 52

Cooley M&A

JANUARY 30, 2024

3] Elliott Management (15 campaigns), Starboard Value (9), Align Partners (8), ValueAct Capital (8) and Ancora (6) topped the activist leaderboard for the year, with JANA Partners and Sarissa Capital Management also highly active in the technology and healthcare sectors. [4]

Private Equity 52

Private Equity M&A Investors Capital 52